COVID-19 is a respiratory disease caused by a new coronavirus (SARS-CoV-2) and causes significant morbidity and mortality. This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study the investigators will analyze the data collected during treatment.
COVID-19 is a novel respiratory disease caused by coronavirus (SARS-CoV-2) and results in significant morbidity and mortality. To date there is no approved medication for the treatment of patients with COVID-19. Remdesivir is a broad-spectrum antiviral nucleotide analogue that inhibits RNA-dependent RNA polymerase activity among a diverse group of RNA viruses. Non-clinical and clinical data suggest that Remdesivir may be useful for the treatment of COVID-19. WHO has identified Remdesivir as a candidate drug of interest to be studied in clinical trials. This retrospective study is designed to analyze the data collected during the routine care of patients who have benefited from this therapy.
Study Type
OBSERVATIONAL
Enrollment
300
This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study we will analyze the data collected during treatment.
Mansoura University Hospital
Al Mansurah, Dakahliya, Egypt
RECRUITINGChange from baseline in Pulse rate
Change from baseline in the pulse rate during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in respiratory rate
Change from baseline in the respiratory rate during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in body core temperature
Change from baseline in the body core temperature during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in blood pressure
Change from baseline in the blood pressure during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in arterial blood gas analyses
Change from baseline in the arterial blood gas analyses during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in Spo2 / FIO2 ratio
Change from baseline in the Spo2 / FIO2 ratio during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in White blood cell count
Change from baseline in the White blood cell count during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in lymphocyte count
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change from baseline in the lymphocyte count during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in lactate dehydrogenase
Change from baseline in the lactate dehydrogenase during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in D-dimer
Change from baseline in the D-dimer during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in procalcitonin
Change from baseline in the procalcitonin during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in Interleukin-6
Change from baseline in the Interleukin-6 during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in Serum ferretin
Change from baseline in the Serum ferretin during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in prothrombin time
Change from baseline in the prothrombin time during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in serum creatinine
Change from baseline in the serum creatinine during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in liver enzyme ALT
Change from baseline in the liver enzyme ALT during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in creatinine kinase
Change from baseline in the creatinine kinase during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in cardiac troponin
Change from baseline in the cardiac troponin during clinical course of patients on Day 15 under treatment with Remdesivir.
Time frame: 15 days
Change from baseline in The Sequential Organ Failure Assessment score (SOFA score)
The Sequential Organ Failure Assessment (SOFA) is a morbidity severity score and mortality estimation tool. It allows for calculation of both the number and the severity of organ dysfunction in six organ systems (respiratory, coagulatory, liver, cardiovascular, renal, and neurologic). The following values are used to calculate the score: (PaO2 / FiO2 and artificial ventilation; platelets; bilirubin; average blood pressure and use of vasoactive drugs; creatinine).The total score ranges from 0-24. Zero indicates low risk while 24 indicates higher risk of mortality.
Time frame: 15 days
Duration of hospitalization
Number of days of hospital admission either in ICU or ward till date of discharge
Time frame: 15 days
Supplemental Oxygen Requirement from Baseline
Duration of increased supplemental oxygen requirement from baseline
Time frame: 15 days
Duration without mechanical ventilation
Duration without mechanical ventilation within 15 days of initiation of treatment with Remdesivir
Time frame: 15 days
Mortality
Mortality at 15 days after initiation of treatment with Remdesivir.
Time frame: 15 days